An accurate genetic diagnosis of maturity-onset diabetes of the young (MODY) is critical for personalized treatment. To avoid misdiagnosis, only genes with strong evidence of causality must be tested. Heterozygous variants in NEUROD1, PDX1, APPL1, and WFS1 have been implicated in MODY, but strong genetic evidence supporting causality is lacking. We therefore assessed their existing genetic evidence and performed gene-level burden tests in a large MODY cohort, alongside two established MODY genes as positive controls (HNF1A- high penetrance, RFX6 -low penetrance). The first reported MODY-associated variants in NEUROD1, PDX1, APPL1, and WFS1 were 0.05). In contrast, variants in NEUROD1 and PDX1 were enriched, albeit at levels comparable to RFX6. Multiple sensitivity analyses corroborated these findings. In summary, rare heterozygous variants in NEUROD1 and PDX1 are low-penetrance causes of MODY, while those in APPL1 and WFS1 lack robust genetic evidence for causality and should not be included in MODY testing panels. Testing genes with limited evidence of causality risks misdiagnosis of maturity-onset diabetes of the young (MODY). There is limited evidence as to whether rare variants in PDX1, NEUROD1, APPL1, and WFS1 cause MODY. Rare damaging variants in APPL1 and WFS1 are not enriched in a MODY cohort, but those in PDX1 and NEUROD1 are, at a level similar to low-penetrance MODY genes. PDX1 and NEUROD1 should be included in MODY gene panels, while heterozygous APPL1 and WFS1 variants should not be reported as causes of MODY.
Sriram et al. (Fri,) studied this question.